Failure-mode evidence depth
Coverage meters, not risk scores. Open the linked section to read direction.Stack
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
How stable is the peptide in biological matrices or protease systems?
What safety, toxicity, or tolerability evidence is attached?
Not availablePolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
3 Ro5 violations · MW 3,949.45 Da
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 30-40 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · bioavailability percent range direct · 12.3 Pharmaco... | Open |
| 2 | 30 % | Comparable | Oral bioavailability in human · human | Route: oral · bioavailability · F· Oral bioavailability in human · Exact ChEMBL pref name PRAMLINTIDE ·... | Open |
| 3 | 30-40 % | Comparable | PepTherDia curated product PK field | Route: SC · 19 · Pramlintide · exact product name match · exact or normalized match | Open |
| 4 | Observation Relative bioavailability of pramlintide was not significantly different between obese and non-obese patients and based on BMI or skin fold thickness. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Pramlintide· 12.3 Pharmacokinetics · bioavailability population similarity text · Relativ... | Open |
| 5 | Observation Injections administered with 6.0-mm and 12.7-mm needles yielded similar bioavailability. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Pramlintide· 12.3 Pharmacokinetics · bioavailability similar with needle lengths text · I... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 11970 pmol*min/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table auc dose 120mcg · Table 5: Mean Ph... | Open |
| 2 | 3750 pmol*min/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table auc dose 30mcg · Table 5: Mean Pha... | Open |
| 3 | 6778 pmol*min/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table auc dose 60mcg · Table 5: Mean Pha... | Open |
| 4 | 8507 pmol*min/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table auc dose 90mcg · Table 5: Mean Pha... | Open |
| 5 | Observation Subcutaneous administration of different doses of SYMLIN into the abdominal area or thigh of healthy individuals showed a linear, dose-dependent increase in maximum plasma concentrations (C max ) and overall exposure (AUC) (Table 5). | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · cmax auc dose dependent increase text · Subcutaneous... | Open |
| 6 | Observation Overall exposure (AUC) to pramlintide is relatively constant with repeat dosing of SYMLIN, indicating no bioaccumulation. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Pramlintide· 12.3 Pharmacokinetics · auc repeat dosing no bioaccumulation text · Overall... | Open |
| 7 | Observation No statistically significant differences were noted in total (AUC 0-∞ ) and peak (C max ) exposure of pramlintide for mild, moderate, and severe renal impairment categories in comparison to patients with normal renal function; although, inter-patient variability in pharmacokinetic parameters was high. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Pramlintide· 12.3 Pharmacokinetics · pramlintide renal impairment auc cmax no significant... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 147 pmol/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table cmax dose 120mcg · Table 5: Mean P... | Open |
| 2 | 39 pmol/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table cmax dose 30mcg · Table 5: Mean Ph... | Open |
| 3 | 79 pmol/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table cmax dose 60mcg · Table 5: Mean Ph... | Open |
| 4 | 102 pmol/L | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table cmax dose 90mcg · Table 5: Mean Ph... | Open |
| 5 | Observation Subcutaneous administration of different doses of SYMLIN into the abdominal area or thigh of healthy individuals showed a linear, dose-dependent increase in maximum plasma concentrations (C max ) and overall exposure (AUC) (Table 5). | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · cmax auc dose dependent increase text · Subcutaneous... | Open |
| 6 | Observation No statistically significant differences were noted in total (AUC 0-∞ ) and peak (C max ) exposure of pramlintide for mild, moderate, and severe renal impairment categories in comparison to patients with normal renal function; although, inter-patient variability in pharmacokinetic parameters was high. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Pramlintide· 12.3 Pharmacokinetics · pramlintide renal impairment auc cmax no significant... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 21 min 1260 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table tmax dose 120mcg · Table 5: Mean P... | Open |
| 2 | 21 min 1260 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table tmax dose 30mcg · Table 5: Mean Ph... | Open |
| 3 | 20 min 1200 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table tmax dose 60mcg · Table 5: Mean Ph... | Open |
| 4 | 19 min 1140 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Pramlintide· 12.3 Pharmacokinetics · pramlintide table tmax dose 90mcg · Table 5: Mean Ph... | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~ 60 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · blood | Pramlintide· 12.3 Pharmacokinetics · plasma binding pramlintide derived from unbound frac... | Open |
| 2 | Observation Pramlintide does not extensively bind to blood cells or albumin (approximately 40% of the drug is unbound in plasma). | Reported | PepTherDia curated product PK field · plasma protein | Route: SC · 19 · Pramlintide · exact product name match · exact or normalized match | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Clearance and half-life evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 2000 mL/h/kg | Comparable | Manual extraction from peer-reviewed supplementary Table S1; apparent clearance CL/F derived from dose/AUC · human · plasma | Route: subcutaneous | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
The identity reference does not expose a sequence string.
No reported sequence notation is available in the current identity references.
No sequence representation
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference link | DistributionExposure Area Under Curve, Bioavailability, Max Concentration, Plasma Protein Binding +1 more | No reported alias | 0 identity 21 evidence |
Reference link | DistributionExposure Bioavailability, Plasma Protein Binding | No reported alias | 1 identity 2 evidence |
PubMed 38691890 | Exposure Bioavailability | No reported alias | 0 identity 1 evidence |
PubMed 41661442 | Persistence Clearance | No reported alias | 0 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0023266' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.